AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Pasithea Therapeutics Corp. Director's Dealing 2022

Aug 16, 2022

35389_dirs_2022-08-16_ba7c194a-fd44-4aa6-be22-95a98a1ec9c6.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Pasithea Therapeutics Corp. (KTTA)
CIK: 0001841330
Period of Report: 2022-08-09

Reporting Person: Delaney David (Member of 10% owner group)
Reporting Person: Concord IP2 Ltd. (Member of 10% owner group)
Reporting Person: Elderhill Corp (Member of 10% owner group)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	226521	Indirect

Footnotes

F1: 191,321 shares are held by Concord IP2, Ltd., of which David Delaney serves as sole director and President, and 35,200 shares are held by Elderhill Corporation, of which David Delaney serves as sole director and President.